
Prescription drug distributor Cencora (COR) is positioned for another potential earnings beat, building on its consistent track record of exceeding analyst expectations by an average of 7.45% over the past two quarters, including an 8.33% surprise last period. The company's current Zacks Earnings ESP of +1.49% combined with a Zacks Rank #2 (Buy) suggests a high probability of a positive surprise in its next earnings report, anticipated on August 6, 2025, according to Zacks research.
Cencora (COR) demonstrates a strong quantitative basis for a potential earnings beat in its upcoming quarterly report, scheduled for August 6, 2025. The company has an established track record of outperformance, exceeding consensus earnings estimates by an average of 7.45% over the past two quarters. This includes a significant 8.33% surprise in the last reported period, where EPS came in at $4.42 versus a $4.08 estimate. Forward-looking indicators reinforce this bullish outlook; Cencora currently holds a Zacks Rank #2 (Buy) and a positive Earnings ESP (Expected Surprise Prediction) of +1.49%. The combination of these two metrics has historically correlated with a positive earnings surprise nearly 70% of the time, suggesting that analysts with the most recent information are revising their forecasts upward ahead of the release.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment